John Zhong
John Zhong is a highly skilled professional with expertise in CAR-T immunotherapy, cancer vaccine, antibody/protein engineering, among others.
He completed his Doctor of Philosophy (Ph.D.) in Molecular Biology at the prestigious University of Cambridge.
With leadership experience, John has served as President & CEO at Gencyte Therapeutics, Inc., and previously held the position of President at Gainegen Technologies LLC.
His academic background includes roles as a Research Assistant Professor at the University of Florida and a Postdoctoral Research Fellow at the University of Colorado Denver.
His competencies encompass areas such as recombinant technology, gene cloning, protein high-expression in various hosts, cell culture, assay development, bioinformatics, and adherence to regulatory standards like 21 CFR, GMP, GLP, FDA, and ICH guidelines.